Stammdaten
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | HOOKIPA Pharma Inc. |
|---|---|
| Ticker | HOOK |
| CIK | 0001760542 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,3 Mio. USD |
| Beta | 0,77 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-03-31 | 10-Q | 2,004,000 | -15,427,000 | -1.23 | 61,256,000 | 34,080,000 |
| 2024-12-31 | 10-Q | -43,500,000 | 82,545,000 | 51,214,000 | ||
| 2024-12-31 | 10-K | 43,946,000 | -43,503,000 | -3.47 | 82,545,000 | 51,214,000 |
| 2024-09-30 | 10-Q | 4,703,000 | -13,841,000 | -1.10 | 109,730,000 | 71,802,000 |
| 2024-06-30 | 10-Q | 1,290,000 | -19,095,000 | -1.52 | 125,046,000 | 86,064,000 |
| 2024-03-31 | 10-Q | 36,599,000 | 14,383,000 | 1.14 | 145,871,000 | 104,522,000 |
| 2023-12-31 | 10-Q | -81,600,000 | 161,337,000 | 89,857,000 | ||
| 2023-12-31 | 10-K | 20,129,000 | -81,580,000 | -8.63 | 161,337,000 | 89,857,000 |
| 2023-09-30 | 10-Q | 6,867,000 | -19,066,000 | -1.73 | 164,010,000 | 95,051,000 |
| 2023-06-30 | 10-Q | 2,679,000 | -18,016,000 | -2.18 | 191,110,000 | 112,330,000 |
| 2023-03-31 | 10-Q | 3,176,000 | -19,680,000 | -0.27 | 163,088,000 | 83,479,000 |
| 2022-12-31 | 10-K | 14,249,000 | -64,915,000 | -9.91 | 170,454,000 | 102,517,000 |
| 2022-12-31 | 10-Q | -64,900,000 | 170,454,000 | 102,517,000 | ||
| 2022-09-30 | 10-Q | 2,230,000 | -18,280,000 | -0.25 | 151,526,000 | 113,348,000 |
| 2022-06-30 | 10-Q | 2,746,000 | -16,356,000 | -0.23 | 172,212,000 | 131,954,000 |
| 2022-03-31 | 10-Q | 1,445,000 | -17,968,000 | -0.40 | 195,711,000 | 147,929,000 |
| 2021-12-31 | 10-Q | -75,700,000 | 126,045,000 | 89,592,000 | ||
| 2021-12-31 | 10-K | 18,448,000 | -75,665,000 | -2.30 | 126,045,000 | 89,592,000 |
| 2021-09-30 | 10-Q | 3,874,000 | -20,040,000 | -0.61 | 142,172,000 | 108,086,000 |
| 2021-06-30 | 10-Q | 5,378,000 | -17,153,000 | -0.52 | 166,156,000 | 125,934,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.